Inpharmica
Overview: The company has been involved in a project aimed at performing phase III of clinical studies on an increased number of patients, including the monitoring of undesired effects and development of documentation to register a new complex pain killer patented in the USA.
Co-investor/Partners: The project has been based on a consortium established in close cooperation with the Medical University of Warsaw.
Innovation: A unique global pain-killer solution carried out on the basis of a patent.
Stage Development/Recent News: The company has successfully managed to prepare stage III of clinical trials and is currently monitoring this process on a study of around 100 patients conducted in cooperation with the Medical University of Warsaw.
Black Pearls VC Partner: Maciej Skórkiewicz
Investment supported by the BRIdge Alfa program of the National Center for Research and Development.